Wednesday, July 8, 2026

Drug profile · INN

methantheline bromide

methantheline bromide (BANTHINE) is a histamine h2 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — methantheline bromide
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

methantheline bromide (BANTHINE) is a histamine h2 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN methantheline bromide
Brand BANTHINE
Mechanism Histamine H2 receptor antagonist
Target Histamine H2 receptor
Route ORAL
Formulation TABLET

Mechanism of action

Histamine H2 receptor antagonist

Primary target: Histamine H2 receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. cimetidine Histamine H2 receptor antagonist
  2. cimetidine hydrochloride Histamine H2 receptor antagonist
  3. famotidine Histamine H2 receptor antagonist
  4. nizatidine Histamine H2 receptor antagonist
  5. ranitidine hydrochloride Histamine H2 receptor antagonist
  6. betazole hydrochloride Histamine H2 receptor agonist

Frequently asked questions

What is methantheline bromide?

methantheline bromide (BANTHINE) is a histamine h2 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for methantheline bromide?

BANTHINE is a marketed brand name for methantheline bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of methantheline bromide?

methantheline bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.